Strong long-term CD data on Humira

New data show that adult moderate-to-severe Crohn's disease patients treated with Abbott Laboratories' Humira (adalimumab) achieved long-term clinical remission and clinical response. Results from the two open-label extension studies, CHARM and GAIN, were presented at the Digestive Disease Week conference, held in late May in San Diego, USA.

The CHARM extension findings demonstrated that three out of four patients (77%) taking Abbott's anti-tumor necrosis alpha antibody drug, who were in remission at the end of the first year, maintained clinical remission for a further year. In addition, the GAIN data showed that, of patients with a clinical response at four weeks, approximately two-thirds achieved clinical response and 40% remained in clinical remission at one year.

CD is a serious, chronic, inflammatory bowel disease that affects more than 500,000 people across Europe, with onset typically before age 40. Over the course of their disease, up to 75% of patients with the condition will undergo surgery for complications or disease resistant to treatment.